2027 Medicare outlook: Via Benefits analysis

The Centers for Medicare & Medicaid Services (CMS) signals flat Medicare Advantage funding, raising new questions for employers and retirees alike.


CMS’s Advance Notice for 2027 points to near-flat funding for Medicare Advantage, even as medical costs continue to rise. With costs outpacing funding, plan changes, pricing pressure, and volatility are likely to accelerate.

What CMS announced

Medicare Advantage capitation increase: 0.09% increase for 2027, far below the 5.06% change in 2026

  • Effective growth rate decline: Down ~4% versus 2026

  • New risk-adjustment rules: Certain diagnoses excluded, reducing plan payments

  • Prescription Drug coverage (Part D) changes continue under the Inflation Reduction Act (IRA):

    • Higher standard deductible and out-of-pocket maximum

    • Continued impact of negotiated drug pricing

Final CMS payment terms are expected in April, with additional Part D information due in July.

Impact to employers sponsoring group Medicare Advantage and prescription drug plans


 

Ongoing rate pressure, following steep increases in prior years

 

 

Continued volatility from unpredictable federal policy shifts

 

 

Added strain from unfavorable Part D risk scoring changes

 

 

Depending on subsidy design, increased costs for retirees and decreasing satisfaction with benefits offered

 

Alternative approach to sponsoring Group Medicare Advantage and Part D Plans:
Transitioning to the individual Medicare market

For plan sponsors
Drives value for retirees while reducing financial and administrative risk

For retirees
Offers broad choice, competitive pricing, and flexibility, even amid market pressure

  • Choice of plan types: Medicare Supplement or Medicare Advantage

  • Medicare Supplement plans provide stable benefits and broad provider access

    • Insulated from federal funding uncertainty affecting Medicare Advantage and Part D

  • Part D out-of-pocket costs remain significantly lower than pre-IRA levels

    • Standalone Prescription Drug Plans continue to benefit from favorable risk-scoring dynamics

  • Individual Medicare Advantage plans provide choice of benefit design and competitive market for millions of members

Note: For employers required to offer group health plans, consider de-coupling Medicare Advantage and Part D coverage.

How Via Benefits can help

We’re here to help you navigate Medicare complexity and discuss the implications of the 2027 CMS guidance with strategies that balance cost predictability, regulatory risk, and retiree choice. Schedule a meeting today by contacting your consultant or visiting solutions.viabenefits.com/contact

Next
Next

What is ICHRA?